Home Page

SOUTH PLAINFIELD, N.J., Feb. 15, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company's business and outlook on Thursday, Feb. 29, at 4:30 p.m. EST.  

To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days.  

About PTC Therapeutics, Inc.  

PTC is a global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, Instagram, LinkedIn, and Twitter at @PTCBio.

For More Information:? 

Investors:? 

Kylie O'Keefe? 

+1 (908) 300-0691? 

kokeefe@ptcbio.com? 

Media:? 

Jeanine Clemente? 

+1 (908) 912-9406? 

jclemente@ptcbio.com? 

View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2023-financial-results-302062052.html

SOURCE PTC Therapeutics, Inc.